博士、副教授

单位：成都理工大学 材料与化学化工学院
电邮：qiuneng168@163.com

基本情况：
　　邱能，博士，2013年于四川大学获博士学位。2010年获英国皇家工程院奖学金资助赴英国格拉斯哥大学生物医学工程学习。国家自然科学基金评审专家，四川省科技厅评审专家，广西壮族自治区科技厅评审专家，北京市科委评审专家，成都市科技局评审专家，四川省药监局评审专家。国际制药工程会员，中国药学会高级会员，中国化工学会会员，四川省药剂学专委会委员，四川省纳米药物专委会委员。入选2016年成都市高新区“金熊猫人才计划”。受邀为polymers，Frontiers in genetics 等特刊编委。并受邀为第一届国际生物技术产业大会（IBC-2017）和第六届国际药物递送大会的等多个国际会议报告人。
　　近年来，致力于前药纳米粒，超分子、脂质体制备技术及冻干技术、MOF材料用于制药废水处理的研究，开发和掌握了可中试放大的药物包合-冻干技术、脂质体放大生产技术、多种脂质体的冻干技术。主持国家自然科学基金1项，四川省科技厅重点研发项目1项，参与多项国家级项目和省级项目（包括国家自然科学基金2项，国家十一五、十二五、十三五重大新药创制项目各1项，省级重大项目2项）。在抗肿瘤新药研发、高端制剂（脂质体）工业化技术开发和转化、冻干技术开发，工业化设备和车间设计等方面积累了丰富的经验。负责和参与了多个国家1类新药的研发工作，其中作为主要负责人参与了国家1.1类新药“注射用和厚朴酚脂质体”的开发工作（负责了脂质体的处方，工艺，质量，稳定性，药效，毒理等研究工作，主持和负责了中试生产，生产工艺开发等研究工作及生产车间和生产设备的设计工作，并参与了临床方案的制订），目前正进行II期临床研究。2024年获中国技术市场协会金桥奖三等奖，在Carbohydr Polym，Desalination，J Mol Struct，J Mol Liq, Eur J Pharm Sci, Int J Nanomedicine，Mat Sci Eng C-Bio S，Int J Nanomedicine等期刊发表SCI论文40余篇，申请国家发明专利20余项，授权国家发明专利7项，申请国际发明专利3项，授权1项。

讲授课程：
本科生课程：制药工艺学，工程项目管理，工程伦理，化工原理实验。
研究生课程：药物制剂与药物研发，慢性病的药物治疗

研究领域：
靶向药物传递系统及药物新制剂，脂质体（产业化技术）、纳米粒、前药、环糊精包合物等复杂制剂、冻干技术，MOF材料。

科研项目：
2022，四川省科技厅重点研发项目，氨基化环糊精金属有机骨架材料的绿色制备及其污染物去除机制的研究，主持
2019，成都理工大学青年骨干教师，主持
2016，国家自然科学基金，倍他环糊精抑制P-gp克服肿瘤多药耐药性与其入胞关系的探讨及相关胞内机制的研究，主持
2014，成都理工大学青年骨干教师，主持
2018，四川省重大科技专项项目， 1 类新药注射用和厚朴酚脂质体治疗非小细胞肺癌的临床研究，主要负责人
2017，国家十三五重大新药创制，注射用和厚朴酚脂质体的Ⅰ期和Ⅱ期临床研究，主要负责人
2012，国家十二五重大新药创制，治疗并增强卵巢癌化疗药物敏感性一类新药HK长效脂质体冻干粉针剂的临床前研究，主研

学术论文：
SCI论文(#共同1作，*通讯作者)
[1]Yao N, Deng L, Weng ZQ, Song Y, Lei N, Liu JD, Qiu N*. Inclusion complex of biotinylated podophyllotoxin with hydroxypropyl-β-cyclodextrin: enhanced solubility, tumor selectivity and efficacy. J Mol Struct. 2026,1361:145666.
[2]Liu XY, Gou CL, Peng W, Wang TD, Yao N, Dai XS, Weng ZQ, Liu JD, Qiu N*. Polyethylene glycol/citric acid cross-linked framework based on aminated cyclodextrin with enhanced water stability for tetracycline hydrochloride removal.J Environ Chem Eng. 2026,14:121097.
[3]Weng ZQ, Sun B, Mei K, Gou CL, Liu JP, Dai XS, Liu XY, Liu JD, Qiu N*. Ultrasound-assisted rapid synthesis of green Na-cyclodextrin MOFs modified with malic acid and polyethylene glycol, and investigation of their adsorption mechanism.Sustain Chem Pharm.2026, 49:102287.
[4]Weng ZQ, Mei K, Sun B, Gou CL, Liu JP, Dai XS, Liu XY, Liu JD, Qiu N*. Citric acid and polyethylene glycol modified Na-cyclodextrin MOFs for efficient antibiotic removal and in-depth investigation of adsorption mechanisms.Environ Res. 2025, 286:122726.
[5]Liu J, Mei K, Dai X, Song Y, Deng L, Liu J, Liu J, Qiu N*. Carrier free nano-assembled redox dual-responsive biotin-artesunate conjugate for enhanced tumor therapy. Eur J Pharm Biopharm. 2025,215:114841.
[6]Gou CL, Weng ZQ, Dai XS, Liu JP, Mei K, Sun B, Qiu N*. Water-stable PEG2000-modified citric acid crosslinked β-CD MOF for efficient removal of tetracycline hydrochloride: synthesis, adsorption behavior, and mechanism.Carbohyd Res. 2025, 557:109631.
[7]Dai X, Jiang D, Gou C, Mei K, Sun B, Liu J, Yao N, Liu X, Qiu N*. Biotinylated Self-Assembled Cytarabine Nano-Prodrug with Enhanced Targetability and Anticancer Efficacy: An In Vitro Study. Langmuir. 2025,41(22):14197-14210.
[8]Dai X, Mei K, Liu J, Sun B, Qiu N.Redox-responsive ferulic acid-biotin conjugate: Design, synthesis, and enhanced anticancer efficacy. Bioorg Med Chem Lett. 2025,122:130209.
[9] Chen L, Liu JB, Gui CX, Mei K, Dai XS, Song Y, Jiang DB, Deng L, Liu JD, Qiu N*. Self-assembled ROS -responsive podollyllotoxin twin drug nanoparticles for enhanced anticancer therapy. J Drug Deliv Sci Tec. 2025, 103:106650. (IF=4.5)
[10] Chen L, Song Y, Deng L, Liu JB, Jiang DB, Dai XS, Mei K, Liu JD, Qiu N*. Self-assembled stimuli-responsive adamantanamine-podophyllotoxin conjugate/β-cyclo- dextrins inclusion complex for enhanced solubility and anticancer activity. J Mol Struct.2025, 1324:140752. (IF=4.0)
[11]Bai P, Li Dan, Shi MS,Yang LY, Tang MH, Qiu N*, Wen Jl. Carrier-free doxorubicin/rhein supramolecular co-assembly for cancer therapy. J Drug Deliv Sci Tec.2023, 89:105030 (IF=5.0)
[12] Ma Y, Chen L, Deng L, Li X, Zhao X, Jiang D, Liu J, Song Y, Liu J, Cui N, Qiu N*. Redox-responsive self-assembled podophyllotoxin twin drug nanoparticles for enhanced intracellular drug delivery. Biomed Mater. 2023,18(4): 045019 (IF=4.0)
[13] Li X, Liu J, Qiu N*. Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy.Polymers (Basel). 2023,15(6):1400. (IF=5.0)
[14] Wen J, Qiu N, Zhu Z, Bai P, Hu M, Qi W, Liu Y, Wei A, Chen L.A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids. Drug Deliv. 2021, 28(1):1055-1066. (IF=6.0)
[15] Zhao X, Qiu N*, Ma YY, Liu JD, An LY, Zhang T, Li ZQ, Han X, Chen LJ.  Preparation, characterization and biological evaluation of β-cyclodextrin-biotin conjugate based podophyllotoxin complex. Eur J Pharm Sci. 2021,160:105745. (IF= 4.6)
[16]Qiu N, Ma YY, Zhao X, An LY, Liu JD, Li XB. Application of Liposome-Based Brug Co-Delivery System for the Reversal of Multidrug Resistance in Cancer Treatment. J Nat Med Res. 2021, 1(1):1-11.
[17]Qiu N*, Zhao X, Liu QM, Shen BLS, Liu JD, Li XB, An LY. Inclusion complex of emodin with hydroxypropyl-β-cyclodextrin: Preparation, physicochemical and biological properties. J Mol Liq. 2019,289: 111151 (IF= 6)
[18]Qiu N*, Li XB, Liu JD. Application of cyclodextrins in cancer treatment. J Incl Phenom Macrocycl Chem. 2017, 89(3-4): 229-246. (IF=2.3)
[19]Qiu N, Shen BLS, Li XB, Zhang XT, An LY, Chen LJ, Wang L, Liu JD. Effect of hydroxypropyl-β-cyclodextrin on solubility, stability and in vitro anti-cancer activity of magnolol. J Incl Phenom Macrocycl Chem. 2016, 85(3): 289-301. (IF=2.3)
[20]Cheng X, Qiu N#, Yang JH, Wen JL, Liu HL, Wang WW, Wang ZF, Wei YQ, Chen LJ. Preparation, characterization, and in vivo study of 7-ethyl-14-aminocamptothecin loaded MPEG-PLA polymeric micelles against H460 human Non-small-cell lung carcinoma. J Pharm Sci. 2015,104(11):3934-42. (IF=3.8)
[21] Qiu N, Cai L, Wang WW, Wang GC, Cheng X, Xu QY, Wen JL, Liu JD, Wei YQ, Chen LJ. Barbigerone Loaded Hydroxypropyl-β-cyclodextrin Liposomal Nanoparticles: Preparation, Characterization and Anti-cancer Activities. Journal of inclusion phenomena and macrocyclic chemistry. J Incl Phenom Macro. J Incl Phenom Macrocycl Chem. 2015, 82: 505-514. (IF=2.3)
[22]Qiu N, Cheng X, Wang G, Wang W, Wen J, Zhang Y, Song H, Ma L, Wei Y, Peng A, Chen L. Inclusion complex of barbigerone with hydroxypropyl-β-cyclodextrin: Preparation and in vitro evaluation.Carbohydr Polym. 2014, 101:623-30.（IF=11.2）
[23]Cai L, Qiu N#, Xiang M, Tong R, Yan J, He L, Shi J, Chen T, Wen J, Wang W, Chen L. Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG2000 micelles.Int J Nanomedicine, 2014:9(1):243-255 (IF=8)
[24]Qiu N, Yin HB, Ji BZ, Klauke N, Glidle A, Zhang YK, Song H, Cai LL, Ma L, Wang GC, Chen LJ, Wang WW. Calcium carbonate microspheres as carriers for the anticancer drug camptothecin. Mat Sci Eng C-Bio S.2012, 32(8): 2634-2640.(IF=7.9)
[25]Cai L, Qiu N#, Li X, Luo K, Chen X, Yang L, He G, Wei Y, Chen L.A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells. Int J Pharm. 2011,408(1-2):173-82.（IF=5.8）
[26] Qiu N, Cai LL, Xie D, Wang G, Wu W, Zhang Y, Song H, Yin H, Chen L.Synthesis, structural and in vitro studies of well-dispersed monomethoxy-poly(ethylene glycol)-honokiol conjugate micelles. Biomed Mater. 2010,5(6):065006. (IF=4.0)

会议论文：
[1] Neng Qiu. Inclusion complex system to improve the solubility and stability of poorly water soluble anti-cancer agents. BIT’s 1st Internation Biotechnology Congress-2017, Xi’an.`
[2] 沈贝莉沙，张继森，蔡帮军，李雪冰，江上， 邱能(*)，刘俊达，安莲英，羟丙基-β-环糊精在提高和厚朴酚水溶性、稳定性方面的应用，中国药学会2015年制药工程专业委员会学术年会，2015.11.20-2015.11.22。

专利：
[1]邱能,孙斌,邓莲. 鬼臼毒素-生物素偶联物及包合物的制备及应用，2025-03-12，中国发明专利，CN202510287612.1.
[2]邱能,代晓霜.阿魏酸-生物素偶联物的制备及应用，2024-11-20，中国，CN 202411659525.6.
[3]邱能,江道斌.生物素-阿糖胞苷前药的制备及其应用，2024-05-10，中国发明专利, CN202410573822.2.  
[4]邱能,宋阳.生物素-青蒿琥酯偶联物及纳米粒的制备及应用，2024-02-07，中国发明专利, CN202410172593.3.
[5)]邱能,刘佳宝.生物素偶联双氢青蒿素的制备及应用，2023-12-22，中国发明专利，CN 2023117781411
[6]邱能,陈磊.一种金刚烷胺鬼臼毒素偶联物/环糊精包合物的制备及应用.中国发明专利, CN 202310195963.0.
[7]邱能,马颖榆. 一种鬼臼毒素孪药纳米粒的制备方法. 中国发明专利，ZL 2021 1 1156210.6
[8]邱能,赵秀. 生物素与环糊精的偶联物及其应用，中国发明专利， CN202010115779.9.
[9]邱能等. 厚朴酚脂质体及其衍生制剂和制备方法，中国发明专利，201510943994.5.
[10]邱能等. 苯基嘧啶衍生物及其制备方法和用途，中国发明专利， 201610671943.6.

中文文章（*通讯作者）：
[1] 张心露,崔楠,邱能*. 生物素在肿瘤靶向递药中的研究进展.药学进展. 2023, 47 (02) :118-124
[2] 李紫沁, 贺颖, 姚辉, 韩雪, 张玉玲, 邱能*. β-环糊精6位修饰衍生物的研究进展化工技术与开发.2021, 322 (03) :33-39+54
[3] 王彦森,邱能*.磺丁基醚-β-环糊精/碳酸钙球霰石微球的制备.化学工程与装备.2017, 244 (05) :8-9.
[4] 沈贝莉莎,安莲英,邱能*,罗丽娜,蔡帮军.厚朴酚脂质体的制备与表征.时珍国医国药2016,  27 (07) :1647-1650.